Latest MLL Stories
First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/
Analyzing the genomes of twin 3-year-old sisters – one healthy and one with aggressive leukemia – led an international team of researchers to identify a novel molecular target that could become a way to treat recurring and deadly malignancies.
A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key "software" instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL).
- Withering but not falling off, as a blossom that persists on a twig after flowering.